BIOLASE, Inc. (BIOL)
Pre-market:
| Previous close | 0.1500 |
| Open | 0.1511 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.1470 - 0.1550 |
| 52-week range | 0.1300 - 32.0000 |
| Volume | |
| Avg. volume | 5,745,830 |
| Market cap | 5.025M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -29.4400 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 24 June 2005 |
| 1y target est | 11.22 |
Insider MonkeyBIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript March 21, 2024 BIOLASE, Inc. beats earnings expectations. Reported EPS is $-1.76, expectations were $-2.56. BIOL isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the BIOLASE Fourth […]
PR NewswireBIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers. The Company is also taking additional steps to optimize operations and believes its revenue-generating strategies and prudent management of its expenses will enable it to achieve its sales and pr
